Independent validation of the PAM50-based chemo-endocrine score (CES) in hormonal receptor positive (HR+)/HER2+ breast cancer (BC) treated with neoadjuvant anti-HER2-targeted therapy
   Google Scholar   
Citation:
Ann Oncol vol 31 (Supplement 2) S17
Meeting Instance:
ESMO Breast 2020
Year:
2020
Type:
Abstract
Sub type:
Poster General
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Following different anti-HER2 combinations in HR+/HER2+ BC across 8 studies: CHERLOB, OptiHER, LPT109096, ICO, HCB, Per-ELISA and C40601.
Methodological:
No
Biospecimen:
Yes
SDC:
No
Parents:
None
Children:
3680  
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
P50-CA58823, R01-CA229409, U10CA180821, U10CA180882  
Corr. Author:
 
Authors:
                                               
Networks:
LAPS-NC007   
Study
CALGB-40601
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: